Investor Presentation February 2025 Safe Harbor Statement Forward-Looking Statements This presentation contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, including, without limitation, statements regarding our ability to build and scale our advanced silicon-anode lithium-ion battery; our production and commercialization timeline; our ability to meet milestones and deliver on our objectives and expectations; our ability to maintain a comp ...

Fourth Quarter 2024 Earnings February 19, 2025 BioMarin regularly uses both GAAP and Non-GAAP results and expectations internally to assess its financial operating performance and evaluate key business decisions related to its principal business activities: the discovery, development, manufacture, marketing and sale of innovative biologic therapies. Because Non- GAAP Income, Non-GAAP Operating Margin percentage, Non-GAAP Diluted EPS, and Non-GAAP Weighted-Average Diluted Shares Outstanding are important int ...

Investor Presentation February 2025 Disclaimer 2 This presentation includes "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements give our current expectations or forecasts of future events. These statements include estimates of future natural gas and oil reserves, expected natural gas and oil production and future expenses, assumptions regarding future natural gas and oil prices, budget ...

SUPPLEMENTAL MATERIALS Fourth Quarter 2024 Quarter Ended December 31, 2024 SUPPLEMENTAL MATERIALS Important Information This presentation contains forward-looking statements. All statements other than statements of historical fact contained in this presentation, including our expectations regarding future expected revenue growth and free cash flow margins, are forward-looking statements. These forward-looking statements are subject to a number of risks, uncertainties and assumptions that may prove incorrect ...

Charles River Laboratories 4Q 2024 Results & 2025 Guidance February 19, 2025 © 2025 Charles River Laboratories International, Inc. Safe Harbor Caution Concerning Forward-Looking Statements. This presentation includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by the use of words such as "anticipate," "believe," "expect," "intend," "will," "may," "estimate," "plan," "outlook," and "project" and other simi ...

Q4 2024 Earnings Call February 19, 2025 Safe Harbor Statement and Non-GAAP Financial Measures Safe Harbor Statement and Non-GAAP Financial Measures Non-GAAP Financial Measures This presentation contains financial measures which have not been prepared in accordance with U.S. generally accepted accounting principles ("GAAP"), including Adjusted EBITDA, Adjusted EBITDA Margin, Adjusted Net Income, Adjusted Diluted EPS, Free Cash Flow, and Free Cash Flow Conversion. Non-GAAP financial measures are not recognize ...

Fourth Quarter Earnings Conference Call 02.19.25 CAUTIONARY STATEMENTS 2 Forward-Looking Statements This presentation contains "forward-looking statements" within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995, including but not limited to statements about Occidental Petroleum Corporation's ("Occidental" or "Oxy") expectations, beliefs, plans or forecasts. Forward-looking statements involve estimates, expectations, projections, goals, forecasts, assumptio ...

Investor Overview February-March 2025 February-March 2025 Investor Presentation 2 Enpro Inc. (NYSE: NPO) | Attractive Portfolio of High-Margin Businesses Company Overview Headquarters Charlotte, NC Principal Manufacturing Facilities 15 Global Employees ~3,500 Financial Overview Market-Cap1 $4.0B LTM Revenue3 $1.0B LTM Adj. EBITDA (Margin)2,3 $255M (24.3%) 2024 YTD Aftermarket Rev. % 54% Dividend Yield1 0.6% 2024 Revenue Contribution Sales by Segment Sales by Channel Sales by Geography Sales by Market Highly ...

AT THE FOREFRONT OF THERAPIES FOR RARE DISEASES FY24 Results Conference Call & Webcast February 19, 2025 Forward-Looking Statements This presentation contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 relating to preclinical and clinical development of our product candidates, the timing and reporting of results from preclinical studies and clinical trials, the prospects and timing of the potential regulatory approval of our product candidates, co ...

2 AGENDA Fourth Quarter 2024 Earnings Results February 19, 2025 Safe Harbor Certain information in this presentation consists of forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the Exchange Act). These statements include statements about Stepan Company's plans, objectives, strategies, financial performance and outlook, trends, the a ...